Found 4355 articles for: ""
A Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development
October 2023 | Volume 22 | Issue 10 | Original Article | 1021 | Copyright © October 2023
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses leading to subsequent scarring and tunnel form...
Read MoreSuccessful Treatment of Lichen Planus With Oral Upadacitinib
October 2023 | Volume 22 | Issue 10 | Case Reports | 1058 | Copyright © October 2023
Lichen planus is an auto-inflammatory skin disorder marked by intensely pruritic, violaceous papules that commonly affect the extremities of middle-aged adults.1 There are several trea...
Read MoreCidofovir in the Management of Non-Genital Warts: A Review
October 2023 | Volume 22 | Issue 10 | Original Article | 1009 | Copyright © October 2023
Introduction: Cutaneous warts are one of the most frequent reasons for visits to the dermatologist. While there are many treatment options available and commonly used to treat wa...
Read MoreIndividual Article: Brodalumab Is an Efficacious, Safe, and Cost-Effective IL-17 Receptor Blocker for the Treatment of Moderate-to-Severe Plaque Psoriasis: 2023 Update
October 2023 | Volume 22 | Issue 10 | Supplement Individual Articles | SF378632s5 | Copyright © October 2023
Psoriasis remains a highly prevalent condition in the United States and worldwide. Preclinical research has been triumphant in elucidating the critical immunological pathways involved in psoriasi...
Read MoreSelection of Nemolizumab Clinical Dosage for Atopic Dermatitis
October 2023 | Volume 22 | Issue 10 | Original Article | 1017 | Copyright © October 2023
Nemolizumab is a monoclonal antibody directed against the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis (AD). Clinical tria...
Read MoreEnsuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic
October 2023 | Volume 22 | Issue 10 | Editorials | 1061 | Copyright © October 2023
It must be ensured that dermatologists practice enhanced antibiotic stewardship to combat antimicrobial resistance and negative consequences of microbiome dysbiosis. In order to help achieve this, we ...
Read MoreParticipant Satisfaction of a Community-based Telehealth Clinic for Atopic Dermatitis
October 2023 | Volume 22 | Issue 10 | Editorials | 1066 | Copyright © October 2023
Atopic dermatitis (AD), a chronic, relapsing inflammatory disease that affects more than 30 million children and adults in the US, disproportionally impacts African American (AA) and Hispanic children...
Read MoreOnychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
October 2023 | Volume 22 | Issue 10 | Original Article | 1040 | Copyright © October 2023
Background: Onychomycosis represents the highest proportion of nail disorders seen in clinical practice. Onychomycosis management may differ amongst specialties, with impact on patien...
Read MoreKeratosis Pilaris: Treatment Practices of Board-Certified Dermatologists
October 2023 | Volume 22 | Issue 10 | Original Article | 985 | Copyright © October 2023
Keratosis pilaris (KP) is a chronic disorder of follicular hyperkeratinization and perifollicular erythema with lesions affecting the extensor surfaces of arms, upper legs, and buttocks. While there i...
Read MoreUpdates in the Treatment of Body-Focused Repetitive Disorders
October 2023 | Volume 22 | Issue 10 | Features | 1069 | Copyright © October 2023
Body-focused repetitive disorders (BFRBs) are psychocutaneous disorders that are underrecognized and undertreated....
Read MoreTopical Ivermectin Is Associated With Improved Erythematotelangiectatic, Papulopustular, and Phymatous Rosacea in a Secondary Analysis
October 2023 | Volume 22 | Issue 10 | Editorials | 1063 | Copyright © October 2023
Rosacea has variable clinical presentation consisting of four overlapping phenotypes: erythematotelangiectatic, papulopustular, phymatous, and ocular.1 Rosacea's pathogenesis involves incre...
Read MoreUnexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade
October 2023 | Volume 22 | Issue 10 | Editorials | 1007 | Copyright © October 2023
In 2017, dupilumab became the first FDA approved systemic therapy for atopic dermatitis. Since its approval, extensive clinical experience and continued research have revealed a number of unexpected e...
Read MoreMechanism of Action of Brodalumab May Correlate With Efficacy in Patients With Inflammatory Skin Diseases
October 2023 | Volume 22 | Issue 10 | Original Article | 994 | Copyright © October 2023
Biologic therapy is used for systemic treatment of multiple inflammatory conditions, including moderate-to-severe plaque psoriasis. Brodalumab is an interleukin-17 (IL-17) receptor A antagonist indica...
Read MoreAnt Venom-Based Ceramide Therapy Is Effective Against Atopic Dermatitis In Vivo
October 2023 | Volume 22 | Issue 10 | Original Article | 1001 | Copyright © October 2023
Background: Atopic dermatitis (AD) is a common skin condition with relatively few therapeutic alternatives. These include corticosteroids, which address inflammation but not superinfe...
Read MoreThe Psychosocial Burden of Skin Disease and Dermatology Care Insights Among Skin of Color Consumers
October 2023 | Volume 22 | Issue 10 | Original Article | 1027 | Copyright © October 2023
Background: Skin conditions are associated with psychological symptoms and may be particularly distressing for skin of color (SoC) individuals. SoC consumers' decisions to pursue derm...
Read MoreAlopecia Areata: The Clinician and Patient Voice
October 2023 | Volume 22 | Issue 10 | Original Article | 967 | Copyright © October 2023
Alopecia areata (AA), an autoimmune disorder of hair follicles, results in varying degrees of scalp, facial, and body hair loss. In addition, it is associated with profound psychosocial and quali...
Read MoreA Review of the Efficacy of Topical Statins for Treating Disseminated Superficial Actinic Porokeratosis
October 2023 | Volume 22 | Issue 10 | Original Article | 1053 | Copyright © October 2023
Porokeratosis is a rare group of acquired or hereditary dermatoses characterized by linear or annular plaques with a keratotic border. DSAP is the most common porokeratosis, and lesions range fro...
Read MoreComparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
October 2023 | Volume 22 | Issue 10 | Original Article | 1017 | Copyright © October 2023
Recently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medica...
Read MoreFULL SUPPLEMENT: Optimizing Transungal Efficacy at the Site of the Infection With Efinaconazole
September 2023 | Volume 22 | Issue 9 | Department | SF378719s5 | Copyright © September 2023
Onychomycosis is a prevalent condition affecting the United States and global population. Treatment options are limited, with only 3 topical anti-fungal medications garnering approval in the US w...
Read MoreINDIVIDUAL ARTICLE: Real-World Evidence on the Use of Calcipotriene and Betamethasone Dipropionate Aerosol Foam 0.005%/0.064% in the Treatment of Psoriasis: A Review of Investigator-Initiated Studies Around the Globe
September 2023 | Volume 22 | Issue 9 | Department | SF378719s5 | Copyright © September 2023
Topical medications are commonly used to manage mild-to-moderate psoriasis and serve as adjunct therapies used in combination with phototherapy and systemic treatments. Fixed-dose calcipotriene (Cal) ...
Read MoreMedia and other results for: ""